Company Filing History:

15 out of 656

Chiron Corporation

patents

4 out of 28

Cetus Oncology Corporation

Years Active: 1994-2003

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6599706 - Recombinant PR-3 and assays employing the same (2003-07-29),

2. 6586222 - Recombinant PR-3 and compositions thereof (2003-07-01),

3. 6071512 - Infective protein delivery system (2000-06-06),

4. 6033667 - Method for detecting the presence of P-selectin (2000-03-07),

5. 5998378 - Compositions for the inhibition of TNF hormone formation and uses thereof (1999-12-07),

6. 5889156 - TNF deletion muteins (1999-03-30),

7. 5888814 - Recombinant host cells encoding TNF proteins (1999-03-30),

8. 5874077 - Human til cells expressing recombinant TNF prohormone (1999-02-23),

9. 5863797 - Gene fusion encoding a hypersecretor protein (1999-01-26),

10. 5849586 - Infective protein delivery system (1998-12-15),

11. 5843693 - Assay method for screening for inhibitors of proTNF conversion (1998-12-01),

12. 5800815 - Antibodies to P-selectin and their uses (1998-09-01),

13. 5702705 - Antibody methods for the treatment of a hormone-mediated disease (1997-12-30),

14. 5686259 - Assay method for the detection of 26kd TNF prohormone (1997-11-11),

15. 5677182 - Cleavage site blocking antibody to prohormone proteins and uses thereof (1997-10-14),

Title: Michael Kriegler: Innovator in Recombinant Proteins

Introduction

Michael Kriegler, based in San Francisco, CA, is a renowned inventor recognized for his significant contributions to biotechnology. With an impressive portfolio of 21 patents, he has played a pivotal role in advancing the field, particularly in the development of recombinant proteins used for medical applications.

Latest Patents

Among his latest patents are innovative methods and materials for producing purified, active recombinant human neutrophil protease, known as PR-3. These patents detail the activation of a pro-form referred to as proPR-3, facilitating the discovery of inhibitors that prevent the excessive release of mature, active TNFα. His research not only focuses on the production of recombinant PR-3 but also explores methodologies for identifying inhibitors that convert the pro-form of TNFα into its active state.

Career Highlights

Michael Kriegler has had a distinguished career, working with prominent companies such as Chiron Corporation and Cetus Oncology Corporation. His experience in these leading biotech firms has greatly enhanced his expertise in the field, enabling him to contribute to groundbreaking research and development.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues, including Carl F. Perez and Robert F. Halenbeck. These partnerships have further propelled innovation in the biotechnology space, driving forward the research that has led to his numerous patents.

Conclusion

Michael Kriegler's work stands as a testament to the remarkable potential of innovative research in biotechnology. His contributions, particularly in the realm of recombinant proteins, are instrumental in shaping future medical therapies and providing solutions for health challenges. With a wealth of patents and collaborations, Michael continues to be a significant figure in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.